Table 3.
Profile of this study’s population and comparison between the atrial fibrillation group and the nonatrial fibrillation group.
| Characteristics | Total participants | Atrial fibrillation by AT-Patch | Atrial fibrillation by AT-Patch or 12-lead ECGa | ||||||||||||
|
|
|
Yes (N=11) | No (N=309) | P value | Yes (N=14) | No (N=306) | P value | ||||||||
| Age (years), mean (SD) | 73.3 (7.83) | 71.9 (11.41) | 73.3 (7.70) | .96 | 73.7 (11.06) | 73.24 (7.68) | .46 | ||||||||
| Age groups, n (%) | |||||||||||||||
|
|
<55 | N/Ab | 1 (9.1) | 9 (2.9) | N/A | 1 (7.1) | 9 (2.9) | N/A | |||||||
|
|
55-64 | N/A | 2 (18.2) | 15 (4.9) | N/A | 2 (14.3) | 15 (4.9) | N/A | |||||||
|
|
65-74 | N/A | 2 (18.2) | 139 (45) | N/A | 3 (21.4) | 138 (45.1) | N/A | |||||||
|
|
>75 | N/A | 6 (54.5) | 146 (47.2) | N/A | 8 (57.1) | 144 (47.1) | N/A | |||||||
| Sex (male), n (%) | 181 (56.6) | 5 (45.5) | 176 (57) | .54 | 8 (57.1) | 27 (87.1) | >.99 | ||||||||
| BMI (kg/m2), mean (SD) | 24.8 (3.21) | 26.2 (4.15) | 24.8 (3.17) | .13 | 25.8 (4.06) | 24.8 (3.17) | .73 | ||||||||
| Heart rate (beats/min), mean (SD) | 67.8 (8.60) | 68.1 (10.38) | 67.7 (8.55) | .98 | 67.4 (9.46) | 67.8 (8.58) | .77 | ||||||||
| Hypertension, n (%) | 236 (73.8) | 8 (72.7) | 228 (73.8) | >.99 | 10 (71.4) | 226 (73.9) | .77 | ||||||||
| Diabetes mellitus, n (%) | 128 (40) | 5 (45.5) | 123 (39.8) | .76 | 5 (35.7) | 123 (40.2) | .96 | ||||||||
| Dyslipidemia, n (%) | 134 (41.9) | 5 (45.5) | 129 (41.7) | >.99 | 6 (42.9) | 128 (41.8) | >.99 | ||||||||
| Heart failure, n (%) | 20 (6.2) | 4 (36.4) | 16 (5.2) | .003 | 6 (42.9) | 14 (4.6) | <.001 | ||||||||
| Previous MIc, n (%) | 72 (22.5) | 1 (9.1) | 71 (23) | .47 | 2 (14.3) | 70 (22.9) | .74 | ||||||||
| Smoking, n (%) |
|
|
|
>.99 |
|
|
.74 | ||||||||
|
|
Current smoker | 38 (11.9) | 1 (9.1) | 37 (12) | N/A | 2 (14.3) | 36 (11.8) | N/A | |||||||
|
|
Former smoker | 102 (31.9) | 3 (27.3) | 99 (32) | N/A | 5 (35.7) | 97 (31.7) | N/A | |||||||
|
|
Never smoker | 180 (56.2) | 7 (63.6) | 173 (56) | N/A | 7 (50) | 173 (56.5) | N/A | |||||||
| History of stroke, n (%) | 38 (11.9) | 1 (9.1) | 37 (12) | >.99 | 1 (7.1) | 37 (12.1) | >.99 | ||||||||
| CKDd, n (%) | 24 (7.5) | 2 (18.2) | 22 (7.1) | .20 | 3 (21.4) | 21 (6.9) | .08 | ||||||||
| Medications, n (%) | |||||||||||||||
|
|
Aspirin | 183 (57.2) | 4 (36.4) | 179 (57.9) | .22 | 5 (35.7) | 178 (58.2) | .17 | |||||||
|
|
P2Y12 inhibitors | 119 (37.2) | 6 (54.5) | 117 (38.1) | .34 | 8 (57.1) | 111 (36.3) | .20 | |||||||
|
|
ACE inhibitorse | 40 (12.5) | 4 (36.4) | 36 (11.7) | .04 | 4 (28.6) | 36 (11.8) | .08 | |||||||
|
|
ARBf | 171 (53.4) | 4 (36.4) | 167 (54) | .40 | 6 (42.9) | 165 (53.9) | .59 | |||||||
|
|
β-blockers | 166 (51.9) | 6 (54.5) | 160 (51.8) | >.99 | 7 (50) | 159 (52) | >.99 | |||||||
|
|
Calcium channel blockers | 130 (40.6) | 3 (27.3) | 126 (41) | .55 | 4 (28.6) | 126 (41.2) | .51 | |||||||
|
|
Statins | 262 (81.9) | 9 (81.8) | 253 (81.9) | >.99 | 11 (78.6) | 251 (82) | .73 | |||||||
| CHA2DS2-VAScg score, mean (SD) | 3.6 (1.25) | 3.8 (1.72) | 3.5 (1.23) | .65 | 3.8 (1.53) | 3.5 (1.23) | .55 | ||||||||
aECG: electrocardiogram.
bN/A: not applicable.
cMI: myocardial infarction.
dCKD: chronic kidney disease.
eACE inhibitors: angiotensin-converting enzyme inhibitors.
fARB: angiotensin receptor blocker.
gCHA2DS2-VASc: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, aged 65-74 years, sex scale.